EBViously
About
EBViously is a spin-off from Helmholtz Munich, focused on developing next-generation vaccines using virus-like particle (VLP) platforms. The company brings together leading experts in Epstein–Barr virus research. Helmholtz Munich has secured over €12 million in funding from the German Center for Infection Research (DZIF) and the Helmholtz Validation Fund (HVF). EBViously has exclusively secured the relevant patent portfolio from Helmholtz Munich for further development and commercialization of the EBV vaccine program.
Areas of activity
Disease Area
Inflammation / Autoimmune DiseasesInfectious DiseasesNeurological Diseases
Technology
Other
Biomedical Research, Medicine, Human Health
Clinical Research, TrialsOther
Representatives
CEO
EBViously